ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards
In Brief: Fidler Wins BMS Cancer Research Award; Thomas Cech To Head Howard Hughs Inst.
Capitol Hill: Bills Seeks Coverage for Treatment Of cancers Found in CDC Screening
Clinical trials: ORI Cites Data Manager For Misconduct; Results Not Affects, NCI Says
Science Policy: NI DOD Begins Project For Common Coding Of Cancer Grants
In Brief: Ahoy! It’s “Admiral Rick”
Professional Societies: AACR Awards Honor 8 Scientists, Clinicians
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
